Dr. Reddy's Laboratories confirms full compliance in FY26 audit

1 min read     Updated on 28 May 2026, 06:13 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Dr. Reddy's Laboratories Limited reported full compliance with SEBI regulations for FY26 following an audit by M/s. Makarand M. Joshi & Co. The report confirmed no deviations, fines, or regulatory actions against the company.

powered bylight_fuzz_icon
41517785

*this image is generated using AI for illustrative purposes only.

Dr. Reddy's Laboratories Limited has confirmed full compliance with the Securities and Exchange Board of India (SEBI) regulations for the financial year ended March 31, 2026. The annual secretarial audit, conducted by M/s. Makarand M. Joshi & Co., Practicing Company Secretaries, verified the company's adherence to the SEBI Act, 1992, the Securities Contracts (Regulation) Act, 1956, and various associated regulations including the Listing Obligations and Disclosure Requirements Regulations, 2015.

The certification process examined the company's documents, records, filings with stock exchanges, and its website. The report confirms that the listed entity complied with all provisions of the reviewed regulations and circulars during the review period. There were no deviations reported, and no fines were imposed.

Compliance Status

The audit assessed the company's adherence to specific governance and operational standards. The following table summarizes the compliance status for key areas:

Sr. No. Particulars Compliance Status
1. Compliance with Secretarial Standards issued by ICSI Yes
2. Adoption and timely updation of policies under SEBI Regulations Yes
3. Maintenance and disclosures on Website Yes
4. Disqualification of Director under Section 164 of Companies Act, 2013 Yes
5. Identification and disclosure of material subsidiary companies Yes
6. Preservation of Documents as per SEBI Regulations Yes
7. Performance Evaluation of Board and Committees Yes
8. Related Party Transactions (RPT) prior approval Yes
9. Disclosure of events or information under Regulation 30 Yes
10. Prohibition of Insider Trading Regulations, 2015 Yes

Regulatory Actions and Observations

The report explicitly states that no actions were taken against the listed entity, its promoters, directors, or subsidiaries by SEBI or the Stock Exchanges during the review period. Additionally, there were no resignations of statutory auditors from the company or its material subsidiaries, and no additional non-compliances were observed.

The audit also noted that the company had complied with SEBI Circular no SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, regarding the disclosure of Employee Benefit Scheme documents. The report, signed by Partner Makarand M. Joshi, assumes the responsibility of management for the authenticity of documents and clarifies that the certification is neither an audit nor an expression of opinion on the financial records.

Historical Stock Returns for Dr Reddys Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.18%-1.39%-2.32%+4.34%+4.85%+23.70%

How will this clean compliance record influence investor confidence and stock performance in the upcoming fiscal year?

What new SEBI regulations or circulars expected in 2026 could pose compliance challenges for Dr. Reddy's?

Will the company leverage its strong governance framework to pursue aggressive expansion or M&A activities?

like19
dislike

Dr. Reddy's Laboratories Records ₹195.39 Crore Block Trade on NSE at ₹1335.70 Per Share

0 min read     Updated on 25 May 2026, 03:03 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Dr. Reddy's Laboratories recorded a block trade on the National Stock Exchange involving approximately 1,462,824 shares at ₹1335.70 per share, with the total deal valued at ₹195.39 crores. Such large-scale block trades are typically executed by institutional investors including mutual funds and foreign portfolio investors to facilitate bulk share transfers while minimizing market impact.

powered bylight_fuzz_icon
41245195

*this image is generated using AI for illustrative purposes only.

Dr. Reddy's Laboratories witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 1,462,824 shares transacted at ₹1335.70 per share. The total deal was valued at ₹195.39 crores, signaling significant institutional participation in the counter.

Block Trade Details

The following table summarizes the key parameters of the block trade recorded on the NSE:

Parameter: Details
Exchange: NSE
Number of Shares: ~1,462,824
Trade Price: ₹1335.70 per share
Total Trade Value: ₹195.39 crores

Block trades of this scale typically indicate large institutional investors—such as mutual funds, foreign portfolio investors, or other institutional entities—executing bulk transactions outside the regular market order book. Such trades are conducted to minimize market impact while facilitating the transfer of significant share quantities between parties.

Historical Stock Returns for Dr Reddys Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-1.18%-1.39%-2.32%+4.34%+4.85%+23.70%

Which institutional investor was the buyer or seller in this block trade, and what does their portfolio strategy reveal about their long-term outlook on Dr. Reddy's Laboratories?

How might this large block trade influence Dr. Reddy's stock price trajectory and retail investor sentiment in the near term?

Could this block trade signal a potential shift in foreign portfolio investor (FPI) positioning in the Indian pharmaceutical sector amid global drug pricing pressures?

like15
dislike

More News on Dr Reddys Laboratories

1 Year Returns:+4.85%